Lik Hang Lee1,2, Lindy Davis3,4, Lourdes Ylagan5, Angela R Omilian6, Kristopher Attwood7, Canan Firat2, Jinru Shia2, Philip B Paty8, William G Cance9. 1. Department of Pathology, University of British Columbia, Vancouver, BC, Canada. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Surgery, Albany Medical College, Albany, NY, USA. 4. Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 5. Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 6. Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 7. Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 8. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9. Department of Surgery, University of Arizona College of Medicine, Phoenix, AZ, USA.
Abstract
BACKGROUND: A challenge in early-stage colorectal cancer (CRC) is identifying biomarkers that predict an increased risk for recurrence. A potential clinically adaptable biomarker is focal adhesion kinase (FAK), a tyrosine kinase that promotes invasion and metastasis. METHODS: An initial, single-institution, 298-patient cohort with all stages of CRC and long-term follow-up was assessed for FAK with tissue microarrays using immunohistochemistry. FAK expression was scored and dichotomized into high and low. Subsequently, a validation cohort of 517 early-stage CRCs from a separate institution was evaluated. All statistical tests were 2-sided. RESULTS: FAK overexpression did not correlate with any known histologic feature and was an early event in CRC, increasing from normal colon to stage I, and stage I to II, but not different at higher stages. High FAK was associated with decreased 10-year recurrence-free survival (RFS) among stage I patients (70.2% for high FAK vs 94.1% for low, P = .02), but not among higher stages in the initial cohort. The same finding was seen in the validation cohort (73.1% for high FAK vs 93.1% for low, P = .004). Multivariable survival analysis for stage I patients showed only two statistically significant factors predicting RFS: FAK (hazard ratio = 5.27, 95% confidence interval = 1.81 to 15.33, P = .002) and perineural invasion (hazard ratio = 7.38, 95% confidence interval = 1.01 to 53.96, P = .049). FAK was the only statistically significant factor in multivariable analysis across RFS, overall, and disease-specific survivals. CONCLUSIONS: High FAK expression identified a subset of stage I CRC patients with high incidence of recurrence and reduced survival, suggesting that FAK has important prognostic value. These patients would immediately benefit from more rigorous surveillance protocols for recurrent disease.
BACKGROUND: A challenge in early-stage colorectal cancer (CRC) is identifying biomarkers that predict an increased risk for recurrence. A potential clinically adaptable biomarker is focal adhesion kinase (FAK), a tyrosine kinase that promotes invasion and metastasis. METHODS: An initial, single-institution, 298-patient cohort with all stages of CRC and long-term follow-up was assessed for FAK with tissue microarrays using immunohistochemistry. FAK expression was scored and dichotomized into high and low. Subsequently, a validation cohort of 517 early-stage CRCs from a separate institution was evaluated. All statistical tests were 2-sided. RESULTS: FAK overexpression did not correlate with any known histologic feature and was an early event in CRC, increasing from normal colon to stage I, and stage I to II, but not different at higher stages. High FAK was associated with decreased 10-year recurrence-free survival (RFS) among stage I patients (70.2% for high FAK vs 94.1% for low, P = .02), but not among higher stages in the initial cohort. The same finding was seen in the validation cohort (73.1% for high FAK vs 93.1% for low, P = .004). Multivariable survival analysis for stage I patients showed only two statistically significant factors predicting RFS: FAK (hazard ratio = 5.27, 95% confidence interval = 1.81 to 15.33, P = .002) and perineural invasion (hazard ratio = 7.38, 95% confidence interval = 1.01 to 53.96, P = .049). FAK was the only statistically significant factor in multivariable analysis across RFS, overall, and disease-specific survivals. CONCLUSIONS: High FAK expression identified a subset of stage I CRC patients with high incidence of recurrence and reduced survival, suggesting that FAK has important prognostic value. These patients would immediately benefit from more rigorous surveillance protocols for recurrent disease.
Authors: Ivar Skaland; Marit Nordhus; Einar Gudlaugsson; Jan Klos; Kjell H Kjellevold; Emiel A M Janssen; Jan P A Baak Journal: Appl Immunohistochem Mol Morphol Date: 2010-01
Authors: Do Youn Park; Hideo Sakamoto; Sandra D Kirley; Shuji Ogino; Takako Kawasaki; Eunjeong Kwon; Mari Mino-Kenudson; Gregory Y Lauwers; Daniel C Chung; Bo R Rueda; Lawrence R Zukerberg Journal: Am J Pathol Date: 2007-11 Impact factor: 4.307
Authors: Patrick Ely Teloken; David Ransom; Ian Faragher; Ian Jones; Peter Gibbs; Cameron Platell Journal: ANZ J Surg Date: 2015-08-02 Impact factor: 1.872
Authors: J K Mooi; P Wirapati; R Asher; C K Lee; P Savas; T J Price; A Townsend; J Hardingham; D Buchanan; D Williams; S Tejpar; J M Mariadason; N C Tebbutt Journal: Ann Oncol Date: 2018-11-01 Impact factor: 32.976
Authors: Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar Journal: Nat Med Date: 2015-10-12 Impact factor: 53.440